Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22760437 | 0.86 | DHPS (0.44) | RPS6KA2ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL16590520 | 0.85 | KMT2A (0.49) | ALDH1A1MAPTKMT2AHPGDTOP1 | |
| SCHEMBL4220947 | 0.85 | KMT2A (0.49) | ALDH1A1MAPTKMT2AHPGDTOP1 | |
| SCHEMBL19802451 | 0.84 | HSP90AA1 (0.46) | RPS6KA2MAPTKMT2ANFE2L2LMNA | |
| SCHEMBL4621308 | 0.82 | CRHR1 (0.46) | RPS6KA2ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL21638093 | 0.81 | HSP90AA1 (0.42) | RPS6KA2ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL28354066 | 0.81 | MAPT (0.44) | ALDH1A1MAPTKMT2AHPGDKDM4E | |
| SCHEMBL4230789 | 0.81 | MAP4K1 (0.52) | RPS6KA2ALDH1A1MAPTKMT2AMAP4K1 | |
| SCHEMBL17836851 | 0.80 | RPS6KA2 (0.52) | RPS6KA2ALDH1A1MAPTKMT2AMAP4K1 | |
| SCHEMBL24601997 | 0.80 | AR (0.43) | RPS6KA2ALDH1A1MAPTNFE2L2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| CN-101203505-A | Chromane and chromene derivatives and uses thereof | WYETH CORP (US) | 2008-06-18 | — | — | CN | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1874756-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | Wyeth (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2006-11-16 | — | — | US | disclosed |
| WO-2006116165-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | HTR1A, HTR2C, CHRM1 | RPS6KA2 2409/4885ALDH1A1 2512/4885MAPT 2730/4885 |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | HTR1A, HTR2C, CHRM1 | RPS6KA2 2409/4885ALDH1A1 2512/4885MAPT 2730/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | RPS6KA2 2668/4885ALDH1A1 814/4885MAPT 3207/4885 |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | HTR2C, HTR1A, HTR3A | RPS6KA2 2165/4885ALDH1A1 190/4885MAPT 2152/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | RPS6KA2 2165/4885ALDH1A1 190/4885MAPT 2152/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | RPS6KA2 751/4885ALDH1A1 283/4885MAPT 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.